Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MISSISSAUGA, Ontario, July 10, 2013 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care™ Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.
Help employers find you! Check out all the jobs and post your resume.
MISSISSAUGA, Ontario, July 10, 2013 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care™ Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.
Help employers find you! Check out all the jobs and post your resume.
